Article may be outdated

This article is 77 days old. Some details may have changed since publication.

Headlinne
Sign inGet Headlinne
PR Newswire·4 min read·hard

First Dual GLP-1/GIP Receptor Agonist Developed for Type 1 Diabetes Shows Promising Benefits in Blood Glucose Control

First Dual GLP-1/GIP Receptor Agonist Developed for Type 1 Diabetes Shows Promising Benefits in Blood Glucose Control
✦AI Summary

A phase 2 clinical trial shows that the drug acmopatide (CT-868) helps patients with type 1 diabetes manage blood glucose levels and reduce body weight. The study suggests this dual-agonist treatment could offer a non-insulin alternative for those struggling with weight gain associated with traditional insulin therapy.

Why it matters

This represents a significant potential advancement in diabetes treatment, addressing the unmet need for therapies that manage both glucose and weight in type 1 patients.

✦Dive DeeperCreate a free account to unlock

Phase 2 Study Results Highlight Use of Once-Daily Injection for Weight Loss and Reduction in Insulin Use

Continue reading on Headlinne

Create a free account to read the full article.

Read full article →
healthscience
Political Bias
Center
LeftLean LCenterLean RRight
Confidence: 95%

The report summarizes clinical trial findings presented at a scientific conference using objective, medical terminology.

Read originalGet full access
✦

Get smarter about the news

Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.

Create free account

Already have an account? Sign in